3.1. Pharmacologic Inhibition of GSK-3 in TKI-Resistant CML Cells Enhances Their Expression of NKG2D Ligands and Susceptibility to NK Cells. This evidence concerns the gene KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.